Talaris Therapeutics

Talaris Therapeutics is the operator of a biotechnology company engaged in the development of innovative cell therapies. The company's proprietary allogeneic cell therapy product has demonstrated the ability to induce tolerance in recipients of solid organ transplants from mismatched and unrelated donors, enabling living kidney transplant recipients to completely eliminate immunosuppression one year post-transplant. The company is developing an innovative proprietary approach to allogeneic hematopoietic stem cell transplantation (Allo-HSCT) that has the potential to transform the standard of care across numerous therapeutic areas. With facilitated Allo-HSCT therapy, our goal is to eliminate the need for chronic immunosuppression in solid organ transplant recipients and to treat patients with severe autoimmune diseases as well as certain severe non-malignant blood, immune, and metabolic disorders.